儿童脓胸胸膜腔内给予链道酶与组织型纤溶酶原激活剂(DTPA):一项随机对照试验的研究方案
本研究方案为一项优效性、安慰剂对照、平行设计、多中心随机对照试验,纳入因脓胸需置入胸管并胸膜腔内给予纤溶酶的既往健康儿童。治疗组胸膜腔内给予组织型纤溶酶原激活剂4 mg后给予链道酶5 mg,安慰剂组给予组织型纤溶酶原激活剂4 mg后给予生理盐水,每日一次共3天。主要结局为胸管置入至出院的时间,次要结局包括达到出院标准时间、胸管留置时间、发热持续时间、额外操作需求、不良事件、再入院、住院费用和死亡。
要点
- 成人脓胸试验显示胸膜腔内给予链道酶α与纤溶酶较单用纤溶酶可缩短住院时间。
- 本方案为优效性、安慰剂对照、平行设计、多中心随机对照试验,纳入需胸管置入和胸膜腔内纤溶酶的既往健康儿童。
- 治疗组给予组织型纤溶酶原激活剂4 mg后给予链道酶5 mg,安慰剂组给予组织型纤溶酶原激活剂4 mg后给予生理盐水,每日一次共3天。
核心结论
- 本多中心随机对照试验将评估链道酶与纤溶酶联合治疗对比单用纤溶酶治疗儿童脓胸的安全性、有效性和成本效果。
研究设计与样本
- 本研究方案为一项优效性、安慰剂对照、平行设计、多中心随机对照试验。
- 参与者为因脓胸入住儿童医院、需要胸管置入并胸膜腔内给予纤溶酶的既往健康儿童。
- 儿童在治疗医生决定需要胸膜腔引流后、胸管置入前进行随机化。
主要发现
- 成人脓胸的随机对照试验显示,与单用纤溶酶相比,胸膜腔内给予链道酶α和纤溶酶的患者住院时间缩短。
- 该治疗策略在儿童中是否安全有效尚不清楚。
关键数值与推荐
- 治疗组胸膜腔内给予组织型纤溶酶原激活剂4 mg,随后给予链道酶5 mg。
- 安慰剂组给予组织型纤溶酶原激活剂4 mg,随后给予生理盐水。
- 研究治疗每日一次,共3天。
- 主要结局为从胸管置入至出院的时间。
- 次要结局包括达到出院标准时间、胸管留置时间、发热持续时间、额外操作需求、不良事件、再入院、住院费用和死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A randomized controlled trial of adults with empyema recently demonstrated decreased length of stay in hospital in patients treated with intrapleurally administered dornase alfa and fibrinolytics compared to fibrinolytics alone. Whether this treatment strategy is safe and effective in children remains unknown. METHODS/DESIGN: This study protocol is for a superiority, placebo-controlled, parallel-design, multicenter randomized controlled trial. The participants are previously well children admitted to a children's hospital with a diagnosis of empyema requiring chest tube insertion and fibrinolytics administered intrapleurally. Children will be randomized after the treating physician has decided that pleural drainage is required but prior to chest tube insertion. After chest tube insertion, participants in the treatment group will receive intrapleurally administered tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg. Participants in the placebo group will receive tPA 4 mg followed by normal saline. Study treatments will be administered once daily for 3 days. All participants, parents or caregivers, clinicians, and research personnel will remain blinded. The primary outcome is length of stay from chest tube insertion to discharge from hospital. Secondary outcomes include time to meeting discharge criteria, chest tube duration, fever duration, need for additional procedures, adverse events, hospital readmission, cost of hospitalization, and mortality. DISCUSSION: This multicenter randomized controlled trial will assess the safety, effectiveness, and cost-effectiveness of combined treatment with dornase alfa and fibrinolytics compared to fibrinolytics alone for the treatment of empyema in children. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01717742 . Registered on 8 October 2012.
引用
- Livingston MH, Mahant S, Ratjen F, et al. Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial. Trials. 2017. PMID: 28646887. doi:10.1186/s13063-017-2026-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。